AT Semicon Adds Business Purpose for Bio Business Promotion at Extraordinary General Meeting... Appoints New Board Members

[Asia Economy Reporter Jang Hyowon] AT Semicon, a total solution company for semiconductor back-end processes, announced on the 30th through the disclosure of the results of the extraordinary general meeting of shareholders that it has added business purposes to promote new pharmaceutical and bio businesses.

The added business purposes include medical diagnostic business, medical vaccine and therapeutic business, quarantine business, and development and sales of vaccines and diagnostic agents. In addition, the issuance limit of convertible bonds was increased through amendments to the articles of incorporation.

At the extraordinary general meeting of shareholders, AT Semicon also appointed new inside and outside directors. The newly appointed inside director, Jeon Byeongmu, is a former executive director of Hyosung ITX and currently serves as a director of the Blockchain Industry Promotion Association and CEO of ITX Marketing.

Baek Jongseon was appointed as an outside director. Outside director Baek Jongseon previously worked in the Administrative Support Division at Seongnam City Hall.

An AT Semicon official stated, “The newly appointed inside and outside directors are professional managers equipped with extensive experience, know-how, and expertise across the company, and are expected to greatly contribute to corporate management and growth.”

This content was produced with the assistance of AI translation services.